Clinical Trial Detail

NCT ID NCT04214067
Title Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to the Usual Radiation Treatment for Newly Diagnosed Early Stage High Intermediate Risk Endometrial Cancer
Recruitment Recruiting
Gender female
Phase Phase III
Variant Requirements No
Sponsors National Cancer Institute (NCI)
Indications

endometrial cancer

Therapies

Pembrolizumab

Age Groups: senior adult

No variant requirements are available.